Simplifying lentiviral downstream processing with a novel affinity resin and robust analytical tools
On demand

Simplifying lentiviral downstream processing with a novel affinity resin and robust analytical tools

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Simplifying lentiviral downstream processing with a novel affinity resin and robust analytical tools

Recombinant lentivirus has become a vector of choice for many gene-modified cell therapies, including several FDA-approved cell therapies, due to the broad tropism and long-term, stable gene expression in non-dividing cells. The safety and efficacy of lentiviral-based therapies depends greatly on optimized and controlled lentiviral production. Downstream purification of lentiviral particles presents unique challenges, and robust analytics are critical to verify both the recovery and infectivity of the purified product.

In this webinar we present an overview of challenges and newly developed solutions for robust lentiviral purification and rapid analytical methods for titer determination and impurity quantification. Details of a new affinity chromatography resin, based on CaptureSelect technology, to purify VSV-G pseudotyped lentivirus, as well as two q-PCR based genomic and proviral infectious titer assays will be discussed.

Attendees will learn about:

  • Current challenges and limitations in lentivirus purification and characterization
  • Development of an affinity resin to purify VSV-G pseudotyped lentivirus to address these challenges
  • Regulatory guidance for lentiviral titers for both cell therapy and viral vector production Internal validation data for two rapid, robust, and QC-amenable assays for lentiviral titers
Chantelle Gaskin
Chantelle Gaskin
Field Applications Scientist Thermo Fisher Scientific

Chantelle is a Field Applications Scientist, specializing in protein and viral vector purification and downstream process development. She held leadership positions at Applied Genetic Technology Corporation and Brammer Bio, prior to joining the Thermo Fisher Scientific Bioproduction Division in 2020. With over 10 years of experience in gene therapy, Chantelle has accumulated comprehensive knowledge of standard industry practices and regulatory standards, applying this knowledge to advance development of therapies for a variety of indications including ocular, CNS and systemic disease.Chantelle holds a Master’s degree in Chemistry from University of Florida and a Bachelor’s in Chemistry from Smith College.

Suzy Brown
Suzy Brown
Senior Field Application Specialist for Pharma Analytics Thermo Fisher Scientific

Suzy Brown is the Senior Field Application Specialist for Pharma Analytics, supporting customers in the UK and Ireland. She has been with Thermo Fisher Scientific for over 5 years where she provides training and implementation of solutions for contaminant and impurity testing designed for the cGMP environment. Prior, she worked in the biopharmaceutical industry as an Analytical Development Scientist for 3 years at Allergan Biologics, within a Molecular Biology team and has experience in molecular methods and impurity testing. Suzy holds a Ph.D in Developmental Biology as well as a Bachelor’s in Cell Biology from University of Manchester (UK).